• Explore /
  • Poster
  • / An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.

An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.

Abstract Video & Slides Poster

Authors

Apostolia Tsimberidou

Apostolia Maria Tsimberidou

The University of Texas MD Anderson Cancer Center, Houston, TX

Apostolia Maria Tsimberidou , Alexandra Drakaki , Danny Khalil , Shivaani Kummar , F. Stephen Hodi , David Yoonsuk Oh , Christopher R. Cabanski , Michael Tezlaff , Theresa LaVallee , Marko Spasic , Leo Nissola , Lacey J. Kitch , Nicholas L. Bayless , Cheryl Selinsky , Jennifer C Ayran , Jill O'Donnell-Tormey , Vanessa M. Hubbard-Lucey , Ute Dugan , James Patrick Allison , Padmanee Sharma

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

PD1/PD-L1 Inhibitor Monotherapy

Clinical Trial Registration Number

03651271

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2573)

DOI

10.1200/JCO.2021.39.15_suppl.2573

Abstract #

2573

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Lorenzo Pilla

First Author: Julie L. Koenig

First Author: Julie L. Koenig

First Author: Thierry Landre